Pimecrolimus
Classification: AATC code: D11AH02
Summary
One study showed similar effect of treatment with pimecrolimus in men and women with Behcet’s disease. Controlled studies on differences between men and women regarding safety and pharmacokinetics are however lacking.
The present evidence concerning differences between men and women is very limited and do not motivate differentiation in dosing or treatment.
Additional information
Pharmacokinetics and dosing
No difference between men and women has been shown for transdermal absorption in general [1].
Effects
A randomized double-blind placebo-controlled study (41 men, 49 women) of treatment with pimecrolimus cream in genital ulcers from Behcet’s disease showed similar effect in men and women [2].
Adverse effects
No studies with a clinically relevant sex analysis regarding adverse effects of pimecrolimus have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Updated: 2019-02-26
Date of litterature search: 2017-03-24
References
- Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21. PubMed
- Chams-Davatchi C, Barikbin B, Shahram F, Nadji A, Moghaddassi M, Yousefi M et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. Int J Rheum Dis. 2010;13:253-8. PubMed
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-03-23.] länk
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson